ANIP Ani Pharmaceuticals Inc
Price (delayed)
$63.26
Market cap
$1.38B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.04
Enterprise value
$1.86B
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers),
Highlights
Ani Pharmaceuticals's revenue has increased by 26% YoY and by 11% from the previous quarter
The gross profit has grown by 19% year-on-year and by 10% since the previous quarter
ANIP's quick ratio is down by 27% year-on-year but it is up by 4.9% since the previous quarter
Ani Pharmaceuticals's net income has shrunk by 199% YoY and by 161% QoQ
The debt has soared by 118% YoY
Key stats
What are the main financial stats of ANIP
Market
Valuations
Earnings
Shares outstanding
21.77M
Market cap
$1.38B
Enterprise value
$1.86B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.3
Price to sales (P/S)
1.99
EV/EBIT
N/A
EV/EBITDA
28.72
EV/Sales
3.02
Revenue
$614.38M
Gross profit
$364.17M
Operating income
-$4.07M
Net income
-$18.52M
EBIT
-$4.61M
EBITDA
$64.65M
Free cash flow
$61.3M
Per share
Balance sheet
Liquidity
EPS
-$1.04
EPS diluted
-$1.04
Free cash flow per share
$3.17
Book value per share
$19.2
Revenue per share
$31.8
TBVPS
$35.3
Total assets
$1.28B
Total liabilities
$855.17M
Debt
$624.09M
Equity
$403.68M
Working capital
$334M
Debt to equity
1.55
Current ratio
2.72
Quick ratio
1.93
Net debt/EBITDA
7.41
Margins
Efficiency
Dividend
EBITDA margin
10.5%
Gross margin
59.3%
Net margin
-3%
Operating margin
-0.7%
Return on assets
-1.8%
Return on equity
-4.7%
Return on invested capital
-0.6%
Return on capital employed
-0.4%
Return on sales
-0.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANIP stock price
How has the Ani Pharmaceuticals stock price performed over time
Intraday
3.03%
1 week
6%
1 month
6%
1 year
-4.93%
YTD
14.44%
QTD
14.44%
Financial performance
How have Ani Pharmaceuticals's revenue and profit performed over time
Revenue
$614.38M
Gross profit
$364.17M
Operating income
-$4.07M
Net income
-$18.52M
Gross margin
59.3%
Net margin
-3%
Ani Pharmaceuticals's net income has shrunk by 199% YoY and by 161% QoQ
The net margin has shrunk by 177% YoY and by 131% QoQ
The company's operating income has shrunk by 128% QoQ and by 108% YoY
ANIP's operating margin has dropped by 126% since the previous quarter and by 107% year-on-year
Growth
What is Ani Pharmaceuticals's growth rate over time
Valuation
What is Ani Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.3
P/S
1.99
EV/EBIT
N/A
EV/EBITDA
28.72
EV/Sales
3.02
The company's EPS has shrunk by 89% QoQ
The P/B is 43% above the 5-year quarterly average of 2.3 and 10% above the last 4 quarters average of 3.0
The company's equity fell by 7% YoY
Ani Pharmaceuticals's revenue has increased by 26% YoY and by 11% from the previous quarter
The price to sales (P/S) is 10% lower than the last 4 quarters average of 2.2 and 5% lower than the 5-year quarterly average of 2.1
Efficiency
How efficient is Ani Pharmaceuticals business performance
The ROA has plunged by 190% YoY and by 100% from the previous quarter
The company's return on sales has shrunk by 144% QoQ and by 108% YoY
Ani Pharmaceuticals's ROIC has plunged by 143% from the previous quarter and by 108% YoY
The return on equity has dropped by 135% since the previous quarter
Dividends
What is ANIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANIP.
Financial health
How did Ani Pharmaceuticals financials performed over time
Ani Pharmaceuticals's total assets is 50% more than its total liabilities
ANIP's total liabilities has surged by 91% year-on-year
Ani Pharmaceuticals's total assets has increased by 42% YoY
The debt is 55% higher than the equity
The debt to equity has soared by 135% YoY
The debt has soared by 118% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.